Proteomics subtyping and circadian dynamics of PDACs to develop novel therapeutic strategies (P11)

PDAC 的蛋白质组亚型和昼夜动态，以开发新的治疗策略 (P11)

• 批准号: 403796231
• 金额: --
• 依托单位: Klinik und Poliklinik für Innere Medizin II: Gastroenterologie
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2018
• 资助国家: 德国
• 起止时间: 2017-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/403796231?language=en
• 关键词: Proteomics; subtyping; circadian; dynamics; PDACs

We will comprehensively study the proteome and phosphoproteome of genetically defined PDAC subtypes over time to achieve mechanistic insights into the cellular metabolism and signaling pathway networks driven by the circadian clock and different oncogenic mutations such as KrasG12D, KrasG12D/Trp53R172H, BrafV637E and Pik3caH1047R. The functional characterization of PDAC subtype specific candidate targets obtained from our proteomics/phosphoproteomics and circadian studies will allow us to pinpoint cancer markers and novel drug targets with the goal to develop subtype-specific chronotherapeutic treatment strategies for this devastating disease.

随着时间的推移，我们将全面研究基因定义的PDAC亚型的蛋白质组和磷酸蛋白质组，以实现对生物钟和不同致癌基因突变(如KrasG12D、KrasG12D/Trp53R172H、BrafV637E和Pik3caH1047R)驱动的细胞代谢和信号通路网络的机械洞察。从我们的蛋白质组学/磷蛋白质组学和昼夜节律研究中获得的PDAC亚型特定候选靶点的功能特征将使我们能够准确定位癌症标记物和新的药物靶点，目标是为这种毁灭性疾病开发亚型特定的时间治疗策略。